FDA Places Clinical Holds on REGENXBIO's RGX-111 and RGX-121 Gene Therapy Programs
Summary
REGENXBIO announced that the FDA placed clinical holds on its RGX-111 and RGX-121 gene therapy programs, with the RGX-111 hold linked to a potential neoplasm in a participant.
Key Events
-
Clinical Hold on RGX-111
The FDA placed a clinical hold on the Phase I/II trial for RGX-111 (Mucopolysaccharidosis type I) following a preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant.
-
Clinical Hold on RGX-121
The FDA also placed a clinical hold on the Phase I/II/III trial for RGX-121 (Mucopolysaccharidosis type II), citing similarities in products, study populations, and shared risk, despite no neoplasm reported in RGX-121 participants.
-
Investigation Ongoing
An investigation is ongoing to determine if the serious adverse event (neoplasm) is drug-related, with preliminary genetic analysis detecting an AAV vector genome integration event associated with proto-oncogene overexpression.
-
Impact on Pipeline
These clinical holds significantly delay the development of two key gene therapy candidates for ultra-rare diseases, creating uncertainty for the company's pipeline and future commercialization efforts.
Analysis
The U.S. Food and Drug Administration (FDA) has placed clinical holds on REGENXBIO's Investigational New Drug (IND) applications for both RGX-111 (for MPS I) and RGX-121 (for MPS II). The hold on RGX-111 follows the preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a study participant. The hold on RGX-121, despite no reported neoplasm in its participants, was cited due to similarities in products, study populations, and shared risk between the clinical studies. This dual clinical hold, particularly with a potential serious adverse event in one program, represents a significant setback for the company's gene therapy pipeline, impacting development timelines and raising safety concerns that could affect investor confidence.
At the time of this filing, RGNX was trading at $8.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $678.9M. The 52-week trading range was $5.04 to $16.19. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.